Acura Pharmaceuticals, Inc. · OTC:ACUR
Acura Pharmaceuticals — Technical Presentation (June 2016)
12 slides from Acura Pharmaceuticals's technical presentation, Jun 8, 2016
Slide 1: Topline Cohort 2 Results Study AP-LTX-400 (Study 400)
CONFIDENTIAL Nasdaq: ACUR Topline Cohort 2 Results Study AP - LTX - 400 (Study 400) June 8, 2016 © 2016 Acura Pharmaceuticals, Inc. All Rights Reserved
Slide 2: General Caution Regarding Forward Looking Statements
Nasdaq: ACUR General Caution Regarding Forward Looking Statements Certain statements in this presentation constitute “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 . Such forwarding - looking statements involve known and unknown risks, uncer
Slide 3: Study 400 Objectives
Nasdaq: ACUR Study 400 Objectives 3 Objectives: • Demonstrate LIMITX technology can retard the release of the active ingredient as 3 or more doses are administered in humans • Demonstrate the LTX - 04 formulation achieves blood levels of drug with 1 and/or 2 tablets equivalent to DILAUDID Observatio
Slide 4: Study 400 Cohort 1 Conclusions
Nasdaq: ACUR 4 Study 400 – Cohort 2 Conclusions Confirmed that the LIMITX technology can effectively slow the release (and absorption) of the active ingredients from the tablets when multiple tablets are ingested Review Study 400 patient level data to gain additional insights on optimizing the LTX -
Slide 5: Study 400 Cohort 2 Design
Nasdaq: ACUR Study 400 Cohort 2 Design 5 30 subjects enrolled 10 taking 6 tablets 10 taking 4 tablets 1 0 taking 8 tablets Single doses of LTX - 04P and DILAUDID taken 1 week a apart with blood samples taken Single doses of LTX - 04P and DILAUDID taken 1 week a apart with blood samples taken Single
Slide 6: Study 400 Formulation Used in Cohort 2
Nasdaq: ACUR 6 Study 400 - LTX - 04P used in Cohort 2 • Identical micro - particle formulation in identical amounts in each dose of LTX - 04P and LTX - 04S • LTX - 04S has 45% less the buffering capacity than LTX - 04P • LTX - 04P was selected for use in cohort 2 LTX-04S LTX-04P 45% Less Buffering (
Slide 7: Study 400 – Extent of Absorption (AUC-inf)
Nasdaq: ACUR 7 Study 400 – Extent of Absorption (AUC 0 - inf. ) 0.00 10.00 20.00 30.00 40.00 50.00 1 Tab 2 Tab 3 Tab 4 Tab 6 Tab 8 Tab Hr * ng/mL DILAUDID LTX-04P • AUC’s for LTX - 04P were comparable to DILAUDID Hydromorphone
Slide 8: Study 400 – Cmax Reduction Based on Relative Change from 1 Tablet Dose
Nasdaq: ACUR 8 Study 400 – Cmax Reduction Based on Relative Change from 1 Tablet Dose (example) 0.0 2.0 4.0 6.0 8.0 10.0 1 2 3 4 6 8 Cmax Plasma Conc. ng/mL DILAUDID 0.0 2.0 4.0 6.0 8.0 10.0 1 2 3 4 6 8 Cmax LTX - 04P 8.4x 6 .8x • Relative calculation required due to Cmax of 1 tablet ~50% lower for
Slide 9: Study 400 – Mean Ratio of Cmax by Dosing Group
Nasdaq: ACUR 9 Study 400 – Mean Ratio of Cmax (ng/mL) by Dosing Group Compared to the 1 Tablet Group for the Same Formulation Dosing in mg DILAUDID LTX - 04P Change 2 Tablet Group 2x 1.9x 2.2x 15% 3 Tablet Group 3x 4.8x 3.8x - 22% 4 Tablet Group 4x 6.4x 4.8x - 25% 6 Tablet Group 6x 6.2x 5.2x - 15% 8
Slide 10: Study 400 Cohort 2 Conclusions
Nasdaq: ACUR 10 Study 400 - Cohort 1 & 2 Conclusions The Limitx Technology can regulate stomach acid and retard the release of active ingredient at 3 or more tablets The current LTX - 04 micro - particle formulation releases drug too slowly for an immediate - release tablet and needs to be reformula
Slide 11: LTX-04 Development Plans
Nasdaq: ACUR 11 LTX - 04 Development Plans • Review Study 400 patient level data for more insights into formulation optimization • Complete LTX - 04 micro - particle and possibly tablet formulation • Discuss Study AP - LTX - 400 results with FDA under FAST TRACK designation • Commence 1 and/or 2 tab
Slide 12: Acura Pharmaceuticals, Inc. contact details
CONFIDENTIAL Nasdaq: ACUR Acura Pharmaceuticals, Inc. 616 N. North Court, Suite 120 Palatine, IL 60067 (847) 705 - 7709 www.AcuraPharm.com www.Nexafed.com www.Oxaydo.com
Acura Pharmaceuticals — Technical Presentation (June 2016) on 6ix